Advanced Search

Home > Journals > Minerva Oftalmologica > Past Issues > Minerva Oftalmologica 2013 June;55(2) > Minerva Oftalmologica 2013 June;55(2):33-7



A Journal on Ophthalmology

Frequency: Quarterly

ISSN 0026-4903


Minerva Oftalmologica 2013 June;55(2):33-7


Efficacy and safety of the fixed combination Timolol 0.5%/Travoprost 0.004% compared the concomitant administration to the single components

Pacella E., Mazzeo G., Mazzeo F., Pacella F., Pasquale N., Mazzeo L.

Department of Ophthalmology, La Sapienza University, Rome, Italy

Aim: Aim of the study was to evaluate the safety and efficacy of the once daily fixed combination timolol 0.5%/ travoprost 0.004% versus twice daily timolol 0.5% associated with once daily travoprost 0.004% in patients with primary open angle glaucoma or ocular hypertension.
Methods: A prospective study was carried out in patients with primary open angle glaucoma (IOP one eye≥ 18 mmHg and ≤30 mmHg and IOP both eyes ≤30 mmHg).The IOP was measured continuously at 15 days, 1 month, 2 months, 3 months, 4 months, 5 months and 6 months after initiation of treatment with timolol 0.5% twice a day, timolol 0.5% twice a day and travoprost 0.004% once daily, and timolol 0.5%/travoprost 0.004% fixed combination once daily.
Results: Eighty eyes of 40 patients, mean age 70.45±10.15 years were treated with only timolol 0.5% for 1 month obtaining a mean reduction in IOP of 9.88%. Switching to timolol 0.5%/ travoprost 0.004% resulted in adequate IOP control (11.3%). After three months of treatment with fixed combination (timolol 0.5%/ travoprost 0.004%) the IOP reduced was statistically significant.
Conclusion: Timolol 0.5%/travoprost 0.004% fixed combination was well-tolerated and produced significant additional IOP reduction when switched from other anti-glaucoma drugs in patients with primary open angle glaucoma or ocular hypertension. Both topical and systemic side-effects were scarce and tolerability was good.

language: English


top of page